EORTC als Beispiel für Vernetzung und Zusammenarbeit in der Krebsforschung

1,337 views

Published on

Prof. Dr. Roger Stupp, Chefarzt Onkologie, USZ und Präsident EORTC 15′. GIST Gruppe Schweiz

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,337
On SlideShare
0
From Embeds
0
Number of Embeds
795
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

EORTC als Beispiel für Vernetzung und Zusammenarbeit in der Krebsforschung

  1. 1. EORTC als Beispiel für Vernetzung und Zusammenarbeit in der Krebsforschung Prof. Dr. med. Roger Stupp European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium & Klinik für Oncology & Tumorzentrum UniversitätsSpital Zürich
  2. 2. Dt: Die Europäische Organisation für Forschung und Therapie von Krebskrankheiten fr: L’organisation européenne de recherche et traitement du cancer EORTC: The European Organisation for Research and Treatment of Cancer 2 Source: EORTC Annual Report 2012 -2013 EORTC aims to develop, conduct, coordinate, and stimulate Pan-European translational and clinical research to improve the standard of cancer treatment for patients, and ultimately increase survival and quality of life. “ ”
  3. 3. Collaborations across many stakeholders 3 Yesterday Tomorrow EORTC Pharma & Biotech AcademiaCharitable Funds EORTC Pharma & Biotech Charitable Funds Academia Gov’t Bodies Payers & Health Insurers Patients Technology Companies Regulators & HTAs ? ?
  4. 4. Einige Tatsachen • Krebs-Häufigkeit  • Krebs-Sterblichkeit  • Aus 10.000 chemischen Substanzen entsteht lediglich ein Arzneimittel
  5. 5. Forschung 5
  6. 6. Drug Development Position of EORTC 6 EORTC
  7. 7. • Private and not for profit organization created in 1962 • Main mission: promote and conduct research to improve cancer care • Core activity: conduct clinical trials  International  Multidisciplinary  Develop new treatments  Define new standards of care  Large academic trials EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER (EORTC) Henri Tagnon, Co-founder of EORTC
  8. 8. EORTC TODAY (2014) • Network of more than 300 institutions from 29 different countries • +/- 2,000 collaborators (clinicians, pathologists, researchers,....) • About 6,000 patients are entered into EORTC trials each year (database of more than 150,000 patients) • 50,000 patients being followed-up • +/-30 trials open to patient entry
  9. 9. ACCRUAL OF PATIENTS IN EORTC STUDIES (2000 – 2011) 71.905 PATIENTS European Union: Austria: 810 Belgium: 7.399 Bulgaria: 49 Cyprus: 73 Czech Republic: 160 Denmark: 529 Estonia: 7 Finland: 34 France: 14.438 Germany: 6.310 Greece: 48 Hungary: 210 Italy: 6.553 Latvia: 34 Luxemburg: 9 Malta: 20 Poland: 1.082 Portugal: 635 Republic of Ireland: 90 Romania: 20 Non-EU Countries Bosnia: 8 Croatia: 352 Macedonia: 6 Norway: 454 Serbia : 261 Russia: 178 Switzerland: 1.438 Turkey: 631 Ukraine: 4 Rest of the World: 3.941 patients European Union (con’t): Slovak Republic: 451 Slovenia: 310 Spain: 2.867 Sweden: 595 The Netherlands: 15.279 United Kingdom: 6.620 9
  10. 10. GIST: a very rare disease Incidence: 10-15/Mio  CH: ca 75 neue Pat/Jahr N Engl J Med 2001; 344:1052-1056
  11. 11. Eur J Cancer 2003, 39:2006-11
  12. 12. Lancet 2004; 364:1127-1134
  13. 13. EORTC 62024 (PI: P. Casalli)
  14. 14. EORTC 62024
  15. 15. EORTC 62062: GIST- Sx ± adj imatinib (years) 0 1 2 3 4 5 6 7 0 10 20 30 40 50 60 70 80 90 100 O N Number of patients at risk : Treatment arm 160 453 344 309 278 207 95 28 121 454 429 410 359 250 105 21 Observation Imatinib adjuvant Relapse free survival (years) 0 1 2 3 4 5 6 7 0 10 20 30 40 50 60 70 80 90 100 O N Number of patients at risk : Treatment arm 29 454 435 425 407 310 143 35 33 454 444 435 413 322 153 31 Observation Imatinib adjuvant Overall Survival Relapse-free survival Overall survival Treatment arm % at 5 Year(s) (98.5% CI) Observation 99.10 (96.99, 99.73) Imatinib Adj. 99.78 (97.49, 99.98) Treatment arm % at 3 Year(s) (98.5% CI) % at 5 Year(s) (98.5% CI) Observation 65.83 (60.00, 71.03) 62.99 (56.93, 68.44) Imatinib Adj. 84.26 (79.48, 88.01) 69.40 (62.97, 74.94) HR (adjusted for R0 vs R1, tumor site and risk group) : HR=0.58 (98.5%CI: 0.43-0.78) P<0.0001 Casalli et al. Proc ASCO 2013
  16. 16. EORTC: Numerous publicatations
  17. 17. Personalized Medicine Frequent Tumors become Rare Harris et al. Discov Med 10(51):144-150, August 2010
  18. 18. Lung cancer is not what it used to be Adenocarcinoma Pao, Nature Med 2012 Small cell lung cancer Non-small cell lung cancer Crizotinib Xalkori® Vemurafenib Zelboraf® Trastuzumab Herceptin® Gefitinib/Erlotinib Iressa®/Tarceva® Cetuximab Erbitux® “Druggable” molecular abberations
  19. 19. Research Requires Infrastructure • Preclinical • Clinical ! "#$% ! "#$%&'(") %#*%#*+, * ! "&' % -. /&'#"01* ! ""' % *2"-"3"1. *%#*4 '#$%5 1* ( ) ) ) % 4 . 3*60'#'6"0*"770'6") %#1* ( ) ! ( % *, 0%8$*6%&78) #9* ! ""** : ; ! <, *%#*-=. *5 . 3* ! "&) * 78#6=*6"/$1*
  20. 20. Collaborations across many stakeholders 20 Yesterday Tomorrow EORTC Pharma & Biotech AcademiaCharitable Funds EORTC Pharma & Biotech Charitable Funds Academia Gov’t Bodies Payers & Health Insurers Patients Technology Companies Regulators & HTAs ? ?
  21. 21. The future of cancer therapy
  22. 22. EORTC PRESIDENTS 1962-2015
  23. 23. towards the future… 23

×